“STAT’s Adam Feuerstein put together all of the burning questions facing the biggest players in biotech, including whether Celgene can change the narrative, if Amgen is headed for a transformation, and, of course, whether Biogen can literally…
“Pharmaceuticals cannot always fix a malfunctioning human body. Sometimes the only way to treat what ails a person is to tinker with their genes: the blueprints for how biological systems are built and how they…
“2018 has so far been another gangbuster year for biotech IPOs: the first three quarters of the year have delivered nearly 50 new biotech offerings, reinforcing the strong new issuance performance of the past 6…
